 3. Unsatisfactory course despite immunosuppressive agents usually azathioprine, methotrexate and two biologic agents usually infliximab, adalimumab andor certolizumab in addition to corticosteroids. Patients should have relapsing and refractory disease despite thiopurines, methotrexate andor infliximabadalimumabcertolizumab maintenance therapy or clear demonstration of intolerance toxicity to these drugs. 